ORGANOZYMES
Nanocatalytic drugs towards Alzheimer's disease
| Coordinatore | KOBENHAVNS UNIVERSITET
Organization address
postcode: 1017 contact info |
| Nazionalità Coordinatore | Denmark [DK] |
| Totale costo | 230˙809 € |
| EC contributo | 230˙809 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2013-IEF |
| Funding Scheme | MC-IEF |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-06-01 - 2016-05-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 | KOBENHAVNS UNIVERSITET | DK | coordinator | 230˙809.80 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Here is proposed nano-scale synthesis and combinatorial screening of medium sized peptide-transition metal catalyst libraries with the aim of producing libraries for screening highly selective catalysts for development of nano-medicines. The implementation of catalytic molecules as medicines is a new paradigm in treatment that can overcome a number of the difficulties with present drugs. As with real enzymes the enzyme capacity of these catalysts comes from productive and selective binding of the TS of reaction. The aim is to develop enzyme like molecules: Organozymes, characterized by high turnover as well as both high chemo- and high regio-selectivity. Novel ligands for transition metals containing functional groups will be synthesized and incorporated into encoded solid phase combinatorial libraries on bio-compatible resins. Encoding ensures extremely fast and simple structure/activity assessment. The screening of split-mix combinatorial libraries of organozymes will have the distinct purpose of developing of artificial proteases as drugs. This involves e. g. Fe, Zn and Cu peptide complexes and combinatorial FRET-substrate screening for proteolytic activity to identify artificial organozyme proteases that act as nano-medicine towards marker proteins in Alzheimers disease. Nano-container delivery of catalytic drugs to target tissue will be developed.'